Keren Machol

Keren Machol


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
KYKezhi Yan
Kezhi Yan
JRJustine Rousseau
Justine Rousseau
KMKeren Machol
Keren Machol
LCLaura A. Cross
Laura A. Cross
KAKatherine E. Agre
Katherine E. Agre
XYXiang-Jiao Yang
Xiang-Jiao Yang
Lysine acetyltransferase 6A (KAT6A) and its paralog KAT6B form stoichiometric complexes with bromodomain- and PHD finger-containing protein 1 (BRPF1) for acetylation of histone H3 at lysine 23 (H3K23). We report that these complexes also catalyze H3K23 propionylation in vitro and in vivo. Immunofluorescence microscopy and ATAC-See revealed the association of this modification with active chromatin. Brpf1 deletion obliterates the acylation in mouse embryos and fibroblasts. Moreover, we identify BRPF1 variants in 12 previously unidentified cases of syndromic intellectual disability and demonstrate that these cases and known BRPF1 variants impair H3K23 propionylation. Cardiac anomalies are present in a subset of the cases. H3K23 acylation is also impaired by cancer-derived somatic BRPF1 mutations. Valproate, vorinostat, propionate and butyrate promote H3K23 acylation. These results reveal the dual functionality of BRPF1-KAT6 complexes, shed light on mechanisms underlying related developmental disorders and various cancers, and suggest mutation-based therapy for medical conditions with deficient histone acylation.

1 January 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KMKeren Machol
Keren Machol
JRJustine Rousseau
Justine Rousseau
SESophie Ehresmann
Sophie Ehresmann
TGThomas Garcia
Thomas Garcia
TNThi Tuyet Mai Nguyen
Thi Tuyet Mai Nguyen
AZAllison Zheng
Allison Zheng

3 October 2019 in Genetics in Medicine
Verified
Journal Article
Closed access
AZAsh Zawerton
Ash Zawerton
CMCyril Mignot
Cyril Mignot
ASAshley Sigafoos
Ashley Sigafoos
PBPatrick Blackburn
Patrick Blackburn
AHAbdul Haseeb
Abdul Haseeb
CDChristel Depienne
Christel Depienne

8 April 2024 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SLShenglan Li
Shenglan Li
SZSen Zhao
Sen Zhao
JSJefferson C. Sinson
Jefferson C. Sinson
ABAleksandar Bajic
Aleksandar Bajic
JRJill A. Rosenfeld
Jill A. Rosenfeld
PLPengfei Liu
Pengfei Liu

26 December 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
KMKeren Machol
Keren Machol
THTrevor D. Hadley
Trevor D. Hadley
JSJake Schmidt
Jake Schmidt
DCDavid Cuthbertson
David Cuthbertson
HTHenri Traboulsi
Henri Traboulsi
CRCathleen Raggio
Cathleen Raggio

5 November 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
KMKeren Machol
Keren Machol
UPUrszula Polak
Urszula Polak
MWMonika Weisz-Hubshman
Monika Weisz-Hubshman
ISI-Wen Song
I-Wen Song
SCShan Chen
Shan Chen
BLBrendan H Lee
Brendan H Lee
Type V collagen is a regulatory fibrillar collagen essential for type I collagen fibril nucleation and organization and its deficiency leads to structurally abnormal extracellular matrix (ECM). Haploinsufficiency of the Col5a1 gene encoding α(1) chain of type V collagen is the primary cause of classic Ehlers–Danlos syndrome (EDS). The mechanisms by which this initial insult leads to the spectrum of clinical presentation are not fully understood. Using transcriptome analysis of skin and Achilles tendons from Col5a1 haploinsufficient (Col5a1+/−) mice, we recognized molecular alterations associated with the tissue phenotypes. We identified dysregulation of ECM components including thrombospondin-1, lysyl oxidase, and lumican in the skin of Col5a1+/− mice when compared with control. We also identified upregulation of transforming growth factor β1 (Tgf-β) in serum and increased expression of pSmad2 in skin from Col5a1+/− mice, suggesting Tgf-β dysregulation is a contributor to abnormal wound healing and atrophic scarring seen in classic EDS. Together, these findings support altered matrix to cell signaling as a component of the pathogenesis of the tissue phenotype in classic EDS and point out potential downstream signaling pathways that may be targeted for the treatment of this disease.